Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | TACR1 | P25103 | 4/20 | 0.30 |
| ▸ | EBP | Q15125 | 1/20 | 0.30 |
| ▸ | DHCR7 | Q9UBM7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL133553 | 0.84 | — | — | |
| SCHEMBL3697821 | 0.83 | — | — | |
| SCHEMBL1535724 | 0.83 | — | — | |
| SCHEMBL6493274 | 0.81 | — | — | |
| SCHEMBL5613970 | 0.80 | ACHE (0.32) | — | |
| SCHEMBL1535713 | 0.77 | — | — | |
| SCHEMBL16754232 | 0.77 | — | — | |
| SCHEMBL1974202 | 0.75 | — | — | |
| SCHEMBL3676398 | 0.74 | — | — | |
| SCHEMBL29733693 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10981932-B2 | Macrocyclic indole derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2021-04-20 | — | — | US | disclosed |
| US-20200087322-A1 | MACROCYCLIC INDOLE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-03-19 | — | — | US | disclosed |
| US-9068052-B2 | Polymerizable composition, crosslinkable resin molded body, crosslinked resin molded body, and laminate | ZEON CORPORATION (JP) | 2015-06-30 | — | — | US | disclosed |
| US-20150087782-A1 | POLYMERIZABLE COMPOSITION, CROSSLINKABLE RESIN MOLDED BODY, CROSSLINKED RESIN MOLDED BODY, AND LAMINATE | ZEON CORPORATION (JP) | 2015-03-26 | — | — | US | disclosed |
| US-7964685-B2 | Polymerizable composition | ZEON CORPORATION (JP) | 2011-06-21 | — | — | US | disclosed |
| US-20100324247-A1 | POLYMERIZABLE COMPOSITION, CROSSLINKABLE RESIN, AND PRODUCTION METHODS AND APPLICATIONS THEREOF | ZEON CORPORATION (JP) | 2010-12-23 | — | — | US | disclosed |
| US-20100252310-A1 | COMPOSITE FOR MULTILAYER CIRCUIT BOARD | KOJIMA KIYOSHIGE | 2010-10-07 | — | — | US | disclosed |
| US-20100144924-A1 | POLYMERIZABLE COMPOSITION | ZEON CORPORATION (JP) | 2010-06-10 | — | — | US | disclosed |
| US-20100015871-A1 | MOLDED ARTICLE, PROCESS FOR PRODUCING THE SAME, AND CROSSLINKED MOLDED ARTICLE AND COPPER-CLAD LAMINATE EACH OBTAINED THEREFROM | ZEON CORPORATION (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2067812-A1 | MOLDED OBJECT, PROCESS FOR PRODUCING THE SAME, AND CROSSLINKED MOLDING AND COPPER-CLAD LAMINATE EACH OBTAINED FROM THE SAME | ZEON CORPORATION (JP) | 2009-06-10 | — | — | EP | disclosed |
| US-20080125531-A1 | Polymerizable Composition, Thermoplastic Resin Composition, Crosslinked Resin, And Crosslinked Resin Composite Materials | ZEON COROPRATION (JP) | 2008-05-29 | — | — | US | disclosed |
| US-20070191563-A1 | Method of manufacturing thermoplastic resin, crosslinked resin, and crosslinked resin composite material | ZEON CORPORATION (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1589054-A1 | POLYMERIZABLE COMPOSITION, THERMOPLASTIC RESIN COMPOSITION, CROSSLINKED RESIN, AND CROSSLINKED RESIN COMPOSITE MATERIALS | Zeon Corporation (JP) | 2005-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981932-B2 | Macrocyclic indole derivatives | CCND2, IDO1, CCNT2 | CYP3A4 362/4885CYP2D6 258/4885CRHR1 518/4885 |
| US-20200087322-A1 | MACROCYCLIC INDOLE DERIVATIVES | CCND2, CCNA1, CCNT2 | CYP3A4 625/4885CYP2D6 413/4885CRHR1 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.